NZ560789A - Dipeptidyl peptidase-IV (DPP-IV) inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent - Google Patents
Dipeptidyl peptidase-IV (DPP-IV) inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agentInfo
- Publication number
- NZ560789A NZ560789A NZ560789A NZ56078906A NZ560789A NZ 560789 A NZ560789 A NZ 560789A NZ 560789 A NZ560789 A NZ 560789A NZ 56078906 A NZ56078906 A NZ 56078906A NZ 560789 A NZ560789 A NZ 560789A
- Authority
- NZ
- New Zealand
- Prior art keywords
- amino
- trifluoromethyl
- oxo
- pyrimidin
- dihydropyrido
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20050027756 | 2005-04-01 | ||
| KR20050053761 | 2005-06-22 | ||
| KR20050085980 | 2005-09-15 | ||
| KR20050122361 | 2005-12-13 | ||
| PCT/KR2006/001169 WO2006104356A1 (en) | 2005-04-01 | 2006-03-30 | Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ560789A true NZ560789A (en) | 2009-11-27 |
Family
ID=37053586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ560789A NZ560789A (en) | 2005-04-01 | 2006-03-30 | Dipeptidyl peptidase-IV (DPP-IV) inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7879848B2 (enExample) |
| EP (1) | EP1863812B1 (enExample) |
| JP (1) | JP4977685B2 (enExample) |
| KR (3) | KR100776623B1 (enExample) |
| CN (1) | CN101151265B (enExample) |
| AR (1) | AR053195A1 (enExample) |
| AT (1) | ATE473976T1 (enExample) |
| AU (1) | AU2006229520B2 (enExample) |
| BR (1) | BRPI0609424B8 (enExample) |
| CA (1) | CA2602248C (enExample) |
| DE (1) | DE602006015443D1 (enExample) |
| DK (1) | DK1863812T3 (enExample) |
| EA (1) | EA012591B1 (enExample) |
| ES (1) | ES2349178T3 (enExample) |
| IL (1) | IL185479A (enExample) |
| MA (1) | MA29586B1 (enExample) |
| MX (1) | MX2007012175A (enExample) |
| MY (1) | MY150102A (enExample) |
| NZ (1) | NZ560789A (enExample) |
| PE (1) | PE20061354A1 (enExample) |
| PL (1) | PL1863812T3 (enExample) |
| PT (1) | PT1863812E (enExample) |
| SI (1) | SI1863812T1 (enExample) |
| TW (1) | TWI357902B (enExample) |
| UA (1) | UA89396C2 (enExample) |
| UY (1) | UY29448A1 (enExample) |
| WO (1) | WO2006104356A1 (enExample) |
| ZA (1) | ZA200708304B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| KR20120030570A (ko) | 2007-04-03 | 2012-03-28 | 미쓰비시 타나베 파마 코퍼레이션 | 디펩티딜 펩티다아제 4 저해 화합물과 감미료와의 병용 |
| CN101357922B (zh) * | 2007-08-02 | 2011-05-18 | 山东轩竹医药科技有限公司 | 新的dpp-iv抑制剂 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| KR20100097725A (ko) * | 2007-12-05 | 2010-09-03 | 아스트라제네카 아베 | 신규 화합물 ⅲ |
| WO2009082134A2 (en) * | 2007-12-21 | 2009-07-02 | Lg Life Sciences, Ltd. | Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| CN101486689B (zh) * | 2008-01-18 | 2011-08-10 | 山东轩竹医药科技有限公司 | 具有磺酰胺基甲酰胺哌嗪结构的dpp-iv抑制剂 |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| JO2870B1 (en) * | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| KR20110136850A (ko) * | 2009-03-13 | 2011-12-21 | 썬 케미칼 비.브이. | 에너지-경화성 조성물에 유용한 사이클릭 카바메이트 화합물 |
| SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| US8871760B2 (en) * | 2009-09-21 | 2014-10-28 | Roche Palo Alto Llc | [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CN102260265B (zh) * | 2010-05-24 | 2015-09-02 | 上海阳帆医药科技有限公司 | 六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途 |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| MY157423A (en) * | 2010-09-03 | 2016-06-15 | Lg Life Sciences Ltd | Production method of intermediate compound for synthesizing medicament |
| TWI519533B (zh) * | 2010-11-01 | 2016-02-01 | Ｌｇ生命科學有限公司 | １－｛（２Ｓ）－２－胺基－４－［２，４－雙（三氟甲基）－５，８－二氫吡啶并［３，４－ｄ］嘧啶－７（６Ｈ）－基］－４－側氧丁基｝－５，５－二氟哌啶－２－酮酒石酸鹽之水合物 |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN105142621A (zh) | 2012-10-24 | 2015-12-09 | 国家健康科学研究所 | 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂 |
| CN105085528A (zh) * | 2014-05-15 | 2015-11-25 | 成都贝斯凯瑞生物科技有限公司 | 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物 |
| EP3273981B1 (en) | 2015-03-24 | 2020-04-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of diabetes |
| JP2019509272A (ja) | 2016-02-23 | 2019-04-04 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 脊髄性筋萎縮症の治療のための併用療法 |
| KR102068754B1 (ko) * | 2017-04-20 | 2020-01-21 | 주식회사 엘지화학 | 의약품 합성용 중간체 화합물의 제조 방법 |
| RU2741389C1 (ru) * | 2017-11-16 | 2021-01-25 | ЭлДжи КЕМ, ЛТД. | Способ получения промежуточного соединения для синтеза лекарственного средства |
| CN108191647B (zh) * | 2018-02-22 | 2020-09-29 | 江苏尚莱特医药化工材料有限公司 | 2,2-二氟二羧酸二烷基酯的合成方法 |
| BR112021002207A2 (pt) | 2018-08-10 | 2021-05-04 | Diapin Therapeutics, Llc | tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios |
| CN111537622B (zh) * | 2019-11-29 | 2021-11-26 | 杭州华东医药集团新药研究院有限公司 | 一种度格列汀及其盐的杂质的检测方法 |
| CN117682981A (zh) * | 2022-09-02 | 2024-03-12 | 中国科学院大连化学物理研究所 | 一种吉格列汀药物前体的制备方法 |
| KR20250097733A (ko) | 2023-12-21 | 2025-06-30 | 이니스트에스티 주식회사 | 디펩티딜 펩티데이즈-iv (dpp-iv) 억제제의 신규한 염, 이의 제조 방법 및 이를 포함하는 약제학적 조성물 |
| KR20250137744A (ko) | 2024-03-11 | 2025-09-19 | 엠에프씨 주식회사 | 제미글립틴의 신규 결정형 및 이의 제조방법 |
| KR20250147756A (ko) | 2024-03-27 | 2025-10-14 | 엠에프씨 주식회사 | 신규한 형태의 제미글립틴 말산염 결정형 및 이의 제조방법 |
| KR20250155700A (ko) | 2024-04-24 | 2025-10-31 | 주식회사 다산제약 | 제미글립틴 산부가염 제조방법 및 이를 유효성분으로 포함하는 dpp-4 저해용 조성물 |
| KR20260008397A (ko) | 2024-07-09 | 2026-01-16 | 주식회사 경보제약 | 제미글립틴 옥살레이트 1 수화물 염 및 이의 제조방법 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| US6861440B2 (en) * | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| WO2003057144A2 (en) * | 2001-12-26 | 2003-07-17 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
| EP1490335B1 (en) * | 2002-03-25 | 2007-09-19 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| CA2483843A1 (en) * | 2002-04-29 | 2003-11-13 | Merck & Co. Inc. | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity |
| WO2004007468A1 (en) * | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| JP2004285325A (ja) * | 2002-12-17 | 2004-10-14 | Fuji Photo Film Co Ltd | パターン形成方法及び物質付着パターン材料 |
| EP1583534A4 (en) * | 2002-12-20 | 2007-08-29 | Merck & Co Inc | 3-AMINO-4-PHENYLBUTANIC ACID DERIVATIVES AS DIPEPTIDYL-PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
| CA2512546A1 (en) | 2003-01-17 | 2004-08-05 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| JP2006516573A (ja) | 2003-01-31 | 2006-07-06 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体 |
| AU2005217642B2 (en) * | 2004-02-23 | 2012-04-12 | Trustees Of Tufts College | Lactams as conformationally constrained peptidomimetic inhibitors |
| US7291427B2 (en) * | 2004-03-19 | 2007-11-06 | Fujifilm Corporation | Surface graft material, conductive pattern material, and production method thereof |
| DE102004020908A1 (de) * | 2004-04-28 | 2005-11-17 | Grünenthal GmbH | Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen |
| DE102005016170A1 (de) * | 2005-04-07 | 2006-10-12 | Grünenthal GmbH | 4,5,6,7- Tetrahydro-isoxazolo(4,5c)pyridin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| CN101218235A (zh) * | 2005-05-10 | 2008-07-09 | 沃泰克斯药物股份有限公司 | 作为离子通道调控剂的二环衍生物 |
| JP2009537558A (ja) * | 2006-05-16 | 2009-10-29 | スミスクライン・ビーチャム・コーポレイション | プロリルヒドロキシラーゼ阻害剤 |
| EP2229395A1 (en) * | 2008-01-17 | 2010-09-22 | Grünenthal GmbH | Substituted sulfonamide derivatives |
-
2006
- 2006-03-21 TW TW095109718A patent/TWI357902B/zh not_active IP Right Cessation
- 2006-03-29 AR ARP060101214A patent/AR053195A1/es active IP Right Grant
- 2006-03-30 US US11/910,370 patent/US7879848B2/en active Active
- 2006-03-30 PE PE2006000351A patent/PE20061354A1/es active IP Right Grant
- 2006-03-30 PT PT06732744T patent/PT1863812E/pt unknown
- 2006-03-30 DE DE602006015443T patent/DE602006015443D1/de not_active Expired - Lifetime
- 2006-03-30 NZ NZ560789A patent/NZ560789A/en unknown
- 2006-03-30 DK DK06732744.5T patent/DK1863812T3/da active
- 2006-03-30 ES ES06732744T patent/ES2349178T3/es not_active Expired - Lifetime
- 2006-03-30 KR KR1020060029138A patent/KR100776623B1/ko not_active Expired - Lifetime
- 2006-03-30 UY UY29448A patent/UY29448A1/es not_active Application Discontinuation
- 2006-03-30 AT AT06732744T patent/ATE473976T1/de active
- 2006-03-30 PL PL06732744T patent/PL1863812T3/pl unknown
- 2006-03-30 UA UAA200710765A patent/UA89396C2/ru unknown
- 2006-03-30 CA CA2602248A patent/CA2602248C/en not_active Expired - Lifetime
- 2006-03-30 EP EP06732744A patent/EP1863812B1/en not_active Expired - Lifetime
- 2006-03-30 CN CN200680009935XA patent/CN101151265B/zh not_active Expired - Lifetime
- 2006-03-30 MY MYPI20061446A patent/MY150102A/en unknown
- 2006-03-30 SI SI200331873T patent/SI1863812T1/sl unknown
- 2006-03-30 JP JP2008503954A patent/JP4977685B2/ja not_active Expired - Lifetime
- 2006-03-30 WO PCT/KR2006/001169 patent/WO2006104356A1/en not_active Ceased
- 2006-03-30 BR BRPI0609424A patent/BRPI0609424B8/pt active IP Right Grant
- 2006-03-30 MX MX2007012175A patent/MX2007012175A/es active IP Right Grant
- 2006-03-30 AU AU2006229520A patent/AU2006229520B2/en not_active Expired
- 2006-03-30 EA EA200701854A patent/EA012591B1/ru unknown
-
2007
- 2007-08-23 IL IL185479A patent/IL185479A/en active IP Right Grant
- 2007-08-28 KR KR1020070086486A patent/KR100794184B1/ko not_active Expired - Lifetime
- 2007-08-28 KR KR1020070086444A patent/KR100830902B1/ko not_active Expired - Lifetime
- 2007-09-28 ZA ZA200708304A patent/ZA200708304B/xx unknown
- 2007-10-30 MA MA30343A patent/MA29586B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2602248C (en) | Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent | |
| US20090312310A1 (en) | Imidazothiazole derivatives | |
| ES2940641T9 (es) | Compuestos que inhiben la proteína MCL-1 | |
| JPWO2009151069A1 (ja) | ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体 | |
| CN114828963A (zh) | 作为Kv1.3钾SHAKER通道阻滞剂的芳基杂二环化合物 | |
| US20250188079A1 (en) | Inhibiting cyclic amp-responsive element-binding protein (creb) | |
| JP2023168413A (ja) | オキソ置換化合物 | |
| JP2022545314A (ja) | プログラニュリンモジュレーターおよびその使用方法 | |
| KR20240070637A (ko) | Trpml의 조정제, 그의 조성물 및 사용 방법 | |
| JP2009298713A (ja) | イミダゾチアゾール誘導体 | |
| JP2023545065A (ja) | オートタキシン抑制剤化合物 | |
| JP2021070691A (ja) | オキソ置換化合物からなる医薬 | |
| EA048618B1 (ru) | Макроциклические ингибиторы rip2-киназы | |
| CA3079557A1 (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| OA16957A (en) | PDE9 inhibitors with imidazo triazinone backbone. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 MAR 2016 BY EARN PTY LTD Effective date: 20121224 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2017 BY EARN PTY LTD Effective date: 20160104 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2018 BY EARN PTY LTD Effective date: 20161230 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2019 BY EARN PTY LTD Effective date: 20180222 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2020 BY MARKPRO GLOBAL COMPANY Effective date: 20190319 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2021 BY MARKPRO GLOBAL COMPANY Effective date: 20200109 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2022 BY MARKPRO GLOBAL COMPANY Effective date: 20210224 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2023 BY MARKPRO GLOBAL COMPANY Effective date: 20220228 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2024 BY MARKPRO GLOBAL COMPANY Effective date: 20230221 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2025 BY MARKPRO GLOBAL COMPANY Effective date: 20240219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2026 BY MARKPRO GLOBAL COMPANY Effective date: 20250221 |